$29.13
+6.2%Tectonic Therapeutic, Inc., a clinical stage biotechnology company focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G-protein coupled receptors(GPCRs). It offers GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines. The company's pipeline products include RXFP1 agonist, which is in ongoing phase 1a and 1b for the indication of heart failure with preserved ejection fraction; GPCR antagonist for indication of hereditary hemorrhagic telangiectasia; bi-functional GPCR modulator for indication of fibrosis; and GPCR modulators. Tectonic Therapeutic, Inc. is based in Watertown, Massachusetts.
Wall Street analysts project that TECX stock may rise significantly over the coming 12 months. The consensus 1-year price target stands at 72.00, with estimates ranging from a low of 60.00 to a high of 81.00.
The consensus 1-year price target stands at 72.00, with estimates ranging from a low of 60.00 to a high of 81.00.
Substantial upside potential. Analysts see significant value gap, suggesting the stock may be materially undervalued at current levels.
Good consensus alignment. Moderate target spread reflects general agreement on value drivers with some variance in assumptions.
Strong buy conviction: High upside with tight consensus suggests compelling investment opportunity backed by analyst confidence.
Rare opportunity: Exceptional upside potential with strong analyst consensus creates a compelling setup. The combination of significant price target premium and tight agreement suggests high-conviction undervaluation that may attract institutional capital.
Analyst skepticism evident—carefully evaluate risks before investment decisions.
Moderate growth expected, typical for mature businesses with stable market positions.
Moderate uncertainty in forecasts—typical for companies with evolving business models.
Mixed signals—some positive indicators offset by concerns about growth or uncertainty.
Significant contraction projected—major business challenges or industry disruption likely.
Moderate coverage—sufficient for guidance but may lack depth of large-cap analysis.
Moderate uncertainty in forecasts—typical for companies with evolving business models.
Analyst skepticism evident—carefully evaluate risks before investment decisions.
Declining estimates with wide disagreement: Analysts projecting contraction without consensus signals significant business uncertainty—exercise caution.
Strong growth expectations signal robust business momentum and market opportunity expansion.
Mixed signals—some positive indicators offset by concerns about growth or uncertainty.
Strong growth expectations signal robust business momentum and market opportunity expansion.
Mixed signals—some positive indicators offset by concerns about growth or uncertainty.
Significant contraction projected—major business challenges or industry disruption likely.
Analyst skepticism evident—carefully evaluate risks before investment decisions.
During the last 12 months, insiders have purchased $2.40M and sold $639K worth of TECX shares, resulting in $1.76M of net buying activity.
0
0.00
18.1K
544.41K
-544K
-$544K
11.0K
235.16K
3.3K
77.63K
+158K
+$158K
62.2K
915.40K
0
0.00
+915K
+$915K
51.0K
1.25M
859
17.02K
+1.2M
+$1.23M
Reicin Alise
Director, Officer: Chief Executive Officer
$498K
Lochner Daniel
Officer: Chief Financial Officer
$275K
Tipirneni Praveen P.
Director
$250K
Springer Timothy A
Director, 10 Percent Owner:
$250K
Donenberg Phillip B.
Director
$250K
Ruddy Marcella K.
Officer: Chief Medical Officer
$363K
Mcnamara Peter
Officer: Chief Scientific Officer
$259K
Reicin Alise
Director, Officer: Chief Executive Officer
$17K
Strong bullish signal with $1.76M net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.
Exceptional buy/sell ratio. Buying dramatically outweighs selling—one of the strongest possible insider signals.
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
5 insider buyers vs. 3 sellers. More insiders buying than selling indicates positive sentiment.
Compelling insider conviction: The combination of strong buy/sell ratio and multiple buyers suggests insiders see attractive risk/reward. Consider this alongside fundamental analysis for confirmation.
Continue your TECX research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.